A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial

Trials

Palle Toft²  Claus Ekstrøm¹  Ulla Lei Larsen²  Aleksander Zincuk²  Sian Robinson² 

[1] Department of Biostatistics, University of Copenhagen, Øster Farimagsgade 5, Copenhagen K DK-1014, Denmark;Department of Anesthesia and Intensive Care, Odense University Hospital, Sdr. Boulevard 29, Odense C DK 5000, Denmark

关键词: Renal recovery;    Neutrophil gelatinase-associated lipocalin;    Continuous renal replacement therapy;    Acute kidney injury;    Pulmonary embolism;    Deep vein thrombosis;    Anti-factor Xa activity;    Critically ill patients;    Thromboprophylaxis;    Enoxaparin;   

Others  :  812619
DOI  :  10.1186/1745-6215-15-226

 received in 2013-12-13, accepted in 2014-05-22,  发布年份 2014

【 摘 要 】

Background

Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at increased risk of venous thromboembolism and yet are often excluded from these trials. We hypothesized that for critically ill patients with acute kidney injury receiving continuous renal replacement therapy, a dose of 1 mg/kg enoxaparin subcutaneously once daily would improve thromboprophylaxis without increasing the risk of bleeding. In addition, we seek to utilize urine output prior to discontinuing dialysis, and low neutrophil gelatinase-associated lipocalin in dialysis-free intervals, as markers of renal recovery.

Methods/Design

In a multicenter, double-blind randomized controlled trial in progress at three intensive care units across Denmark, we randomly assign eligible critically ill adults with acute kidney injury into a treatment (1 mg/kg enoxaparin subcutaneously once daily) or control arm (40 mg enoxaparin subcutaneously once daily) upon commencement of continuous renal replacement therapy.

We calculated that with 133 patients in each group, the study would have 80% power to show a 40% reduction in the relative risk of venous thromboembolism with 1 mg/kg enoxaparin, at a two-sided alpha level of 0.05. An interim analysis will be conducted after the first 67 patients have been included in each group.

Enrolment began in March 2013, and will continue for two years. The primary outcome is the occurrence of venous thromboembolism. Secondary outcomes include anti-factor Xa activity, bleeding, heparin-induced thrombocytopenia, filter lifespan, length of stay, ventilator free days, and mortality. We will also monitor neutrophil gelatinase-associated lipocalin and urine volume to determine whether they can be used as prognostic factors for renal recovery.

Discussion

Critically ill unit patients with acute kidney injury present a particular challenge in the provision of thromboprophylaxis. This study hopes to add to the growing evidence that the existing recommendation of 40 mg enoxaparin is inadequate and that 1 mg/kg is both safe and effective for thromboprophylaxis.

In addition, the study seeks to identify predictors of renal recovery allowing for the proper utilization of resources.

Trial Registration

EU Clinical Trials Register: EudraCT number: 2012-004368-23, 25 September 2012.

【 授权许可】

   
2014 Robinson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cruz DN, De CM, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C: Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010, 36:444-451.
• [2]Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'amico G, Goldsmith D, Devarajan P, Bellomo R: Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 2010, 36:452-461.
• [3]Kumpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, Faulhaber Walter R, Kielstein JT: Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care 2010, 14:R9. BioMed Central Full Text
• [4]de Geus HR, Bakker J, Lesaffre EM, le Noble JL: Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am J Respir Crit Care Med 2011, 183:907-914.
• [5]Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD: the Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000, 161:1109-1114.
• [6]Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE: Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011, 364:1305-1314.
• [7]Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH: Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001, 161:1268-1279.
• [8]Ocak G, Vossen CY, Rotmans JI, Lijfering WM, Rosendaal FR, Parlevliet KJ, Krediet RT, Boeschoten EW, Dekker FW, Verduijn M: Venous and arterial thrombosis in dialysis patients. Thromb Haemost 2011, 106:1046-1052.
• [9]Cook DJ, Douketis J, Arnold D, Crowther MA: Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Curr Opin Pulm Med 2009, 15:455-462.
• [10]Cook DJ, Crowther MA: Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med 2010, 38:S76-S82.
• [11]Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ: Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007, 30:E93-E102.
• [12]Chan CM, Shorr AF: Venous thromboembolic disease in the intensive care unit. Semin Respir Crit Care Med 2010, 31:39-46.
• [13]Minet C, Lugosi M, Savoye PY, Menez C, Ruckly S, Bonadona A, Schwebel C, Hamidfar-Roy R, Dumanoir P, Ara-Somohano C, Ferretti GR, Timsit JF: Pulmonary embolism in mechanically ventilated patients requiring computed tomography: prevalence, risk factors, and outcome. Crit Care Med 2012, 40:3202-3208.
• [14]Shorr AF, Williams MD: Venous thromboembolism in critically ill patients: observations from a randomized trial in sepsis. Thromb Haemost 2009, 101:139-144.
• [15]Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI: Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133:141S-159S.
• [16]Ho KM, Chavan S, Pilcher D: Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011, 140:1436-1446.
• [17]Robinson S, Zincuk A, Larsen UL, Ekstrom C, Nybo M, Rasmussen B, Toft P: A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: double-blinded, randomized controlled trial. Crit Care 2013, 17:R75. BioMed Central Full Text
• [18]Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A: Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4:759-765.
• [19]Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B: Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997, 350:1795-1798.
• [20]Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J: Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000, 83:416-420.
• [21]Fleming TR, Harrington DP, O'Brien PC: Designs for group sequential tests. Control Clin Trials 1984, 5:348-361.
• [22]Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228.